跳至主要内容
临床试验/DRKS00028920
DRKS00028920已完成不适用

Post-marketing effectiveness of a digital therapeutic for unspecific and degenerative back, hip and knee pain during an extended probation period: An observational study of patient-reported outcome data

Vivira Health Lab GmbH0 个研究点目标入组 7,842 人开始时间: 2022年7月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
7,842

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1. prescription of the DiGA Vivira with one of the above diagnoses (back, hip, and knee diagnosis groups) by a health care provider; 2. an initial pain intensity of > 0 on the VNRS (0-10); 3. any specified duration of pain (acute, subacute, chronic); 4. at least one completed exercise

排除标准

  • Any exclusion criterion according to the approval of the use by the Federal Institute for Drugs and Medical Devices (BfArM) (https://diga.bfarm.de/de/verzeichnis/387).

研究者

相似试验